If you’ve ever searched for ways to practice coding or prep for tech interviews, you’ve probably seen LeetCode mentioned ...

The ongoing TikTok-US saga seems close to reaching a conclusion, but we’re not there yet. As details get worked out for a potential Oracle-driven deal, a new Bloomberg report details the plans for ...

Kelley Cotter has received funding from the National Science Foundation. President Donald Trump announced on Sept. 19, 2025, a preliminary agreement for the sale of a majority stake in TikTok from ...

TikTok engages more than 170 million Americans with its endless scroll and viral content, but as a potential sale for the popular platform nears, experts are concerned about the future of the app's ...

An exclusive excerpt from Every Screen On The Planet reveals how the social media app’s powerful recommendation engine was shaped by a bunch of ordinary, twentysomething curators—including a guy named ...

A senior official in President Donald Trump’s administration says Oracle will receive a copy of TikTok's algorithm to operate for U.S. users WASHINGTON -- Tech giant Oracle will receive a copy of the ...

TikTok will not shut down on Wednesday, as President Donald Trump inches nearer to closing a deal with China that will most likely see the app's majority ownership shift to US owners and US-based ...

The White House has answered what had been one of the major outstanding questions regarding its pending deal to transfer TikTok’s US operations to a majority American ownership group: Under the ...

The US version of TikTok will reportedly still use the Chinese algorithm, but the American investors will have control over it. The latest report comes just a day after a deal with the US and China ...

A TikTok deal could be announced this week, according to White House officials. New details have emerged that suggest several new and old investors, including Oracle and private-equity firm Silver ...

Pancreatic cancer remains one of the biggest challenges in the field of oncology. Numbers of cases are increasing, and the latest personalized therapies and immunotherapy are not yet yielding results.